适形放疗联合化疗治疗局部晚期肺癌的临床研究

目的评价适形放疗联合化疗治疗局部晚期非小细胞肺癌的近期疗效和急性毒副反应.方法2001年4月～2002年12月采用泰素,顺铂与三维适形放疗同步治疗43例Ⅲ期非小细胞肺癌患者.化疗方案为泰素135mg/,顺铂70mg/,第1,29,57天.三维适形放疗放射源为6MVX线,2Gy·(次·天)-1,40Gy后缩野加量,总剂量DT66～70Gy.结果近期结果显示,肺原发灶有效率为88.4%(38/43),一年及两年生存率分别为55.8%(24/43)和39.5%(17/43).急性毒副反应主要是骨髓抑制,胃肠道反应和较中度放射性食管炎,放射性肺炎,经处理后均可耐受.结论泰素联合三维适形放疗能提高局部晚期非小细胞肺癌的近期疗效,且急性毒副反应无明显增加,值得进一步随访研究.

三维适形放疗联合化疗治疗肺癌局部复发的临床效果评价

目的 探究三维适形放疗联合化疗对肺部局部复发患者的临床治疗效果。方法 选取我院2014年3月-2015年4月期间收治的86例肺癌局部复发患者,按照入院的先后顺序将其分为观察组以及对照组,每组43例。对照组采用常规放疗联合化疗方案进行治疗,观察组采用三维适形放疗联合化疗方案进行治疗,对两组患者的疗效进行对比。结果 两组患者经治疗后,其观察组患者的治疗效果好于对照组患者,两组间通过比较,P〈0.05,差异具有统计学意义。结论 对肺癌局部复发患者采用三维适形放疗联合化疗进行治疗,其治疗效果较为显著,具有临床应用价值。

不同照射野三维适形放疗在局部晚期非小细胞肺癌中的应用

目的:分析不同照射野三维适形放疗在局部晚期非小细胞肺癌中的应用价值。方法:回顾性分析2005年1月至2008年6月收治的132例局部晚期非小细胞肺癌患者资料,均行三维适形放疗,依据照射野的不同,分成3野组与5野组,常规分割进行照射,5次/周,DT60Gy-66Gy/30f-33f。观察两组患者近期疗效、V30、V20、V15、V10、V5等参数以及放射性肺炎的发生,并进行比较。结果:两组患者之间近期疗效(CR+PR)、V20、放射性肺炎的发生均无差异(P>0.05);3野组V30、V15、V10高,而5野组V5较高,V30、V10、V5具有非常显著差异(P<0.01),V15具有显著差异(P<0.05)。结论:采用3野或5野进行照射,效果相似。

三维适形放疗联合化疗治疗肺癌局部复发的疗效观察

Objective To observe the recent clinical efficacy and safety of three-dimensional conformal radiotherapy combined with chemotherapy in the treatment of local recurrence advanced non-small cell lung cancer.Methods 80 patients with advanced non-small cell lung cancer patients were randomly divided into two groups,treatment group 40 cases,three-dimensional conformal radiotherapy combined with chemotherapy:three-dimensional conformal radiotherapy using linear accelerators,6MV-X ray,CT simulation,radiation measured as the 60～ 70GY,6～7weeks to complete radiotherapy,chemotherapy program using low-dose TP:paclitaxel and cisplatin 30mg + 30mg,1 per week for 5 to 6 weeks,concurrent chemotherapy on the first day of radiotherapy.Control group,40 patients,using conventional radiotherapy combined with chemotherapy,radiotherapy with conventional external beam linear accelerator,chemotherapy with the treatment group.Both groups were at 2 months after the end of treatment evaluated.Results 80 cases completed the treatment group and a total effective rate year survival rate,2-year survival rate was significantly higher,the difference was statistically significant(P0.05).Toxicity difference was not significant(P0.05).Conclusion Three-dimensional conformal radiotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer have better short-term local recurrence of the efficacy,safety,good,worthy to be widely used.supports all the CNKI file formats;only supports the PDF format.

三维适形加量放疗联合化疗治疗非小细胞肺癌的临床观察

目的:观察常规分割放疗基础上行三维适形加量放疗并联合化疗治疗非小细胞肺癌的可行性及疗效.方法:将68例Ⅱ～Ⅲ期非小细胞肺癌患者先予NP方案化疗(盖诺40mg,静脉注入,d1,d8;DDP40mg,静脉滴入,d1～d3).鳞癌化疗1个周期,其他类型肺癌化疗2个周期.放射治疗的前半程为常规分割2Gy/次,剂量40Gy/20次后改用三维适形加量放疗5Gy/次,每次间隔1～2d,剂量30Oy/6次.锁骨上有淋巴结转移者采用6MVX线加电子线常规分割放疗至总量Dτ 60Gy.放射治疗结束后根据患者情况再追加化疗2～4个周期.结果:68例患者全部完成治疗计划,其中肺原发灶完全缓解(CR)12例,部分缓解(PR)49例,稳定无进展(NR)7例,总有效率为84.7%.Ⅰ～Ⅱs级急性放射性食管炎64%,Ⅲ级急性放射性食管炎5%,急性放射性气管炎,肺炎35%,急性胃肠道反应64%,治疗期间白细胞下降的发生率100%,升白治疗有效.后期毒副反应主要是放射性肺纤维化38%.1,2年生存率分别为71.2%和52%,1,2年局控率为85%和71%.结论:在常规分割放疗基础上行三维适形加量放疗并联合化疗治疗非小细胞肺癌有较好的近期疗效,毒副反应可耐受,值得进一步观察和推广.

含铂方案同步三维适形放疗治疗局部晚期非小细胞肺癌78例临床观察(英文)

Objective: The aim of our study was to explore the short-term efficacy of platinum-based combined with concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer(NSCLC). Methods: Between 2006 to 2010, 78 cases of locally advanced NSCLC were enrolled into this trial. All patients were given platinum-based chemotherapy combined with concurrent three-dimensional conformal radiotherapy(3-DCRT). Chest CT scans were obtained during end-expiratory and end-inspiratory pauses when performing positioning. Image fusion was done after the image data was transferred to treatment plan system(TPS). The target volume was delineated on the fusion images. The chemotherapy was given on the first day of radiotherapy. Comprehensive examinations were conducted 4–6 weeks after concurrent chemoradiotherapy to assess short-term efficacy. Results: Complete remission(CR) was achieved in 8 cases and partial remission(PR) in 54 cases. The efficiency rate reached 79.5%. Grade III–IV radiation esophagitis occurred in 11.5%. No exit and death cases during treatment. Conclusion: Concurrent chemo-radiotherapy could significantly improve the short-term efficacy and prolong survival of stage III NSCLC, meanwhile the adverse reactions could be tolerated.